Here's Why Heat Biologic Shares Are Hot This Morning

Shares of Heat Biologics HTBX traded higher on Wednesday after the company disclosed its move to advance their biomarker discovery alliance with Adaptive Biotechnologies.

The company indicated that Adaptive would use its patented immune profile assay known as immunoSEQ to allow a detailed immune response characterization to its ImPACT and ComPACT-based immunotherapies. This included Heat's second stage product candidate, HS-410, for non-muscle invasive bladder cancer.

Heat Biologics indicated that when used to assess the platform's mechanism, the immunoSEQ Assay offers a considerable biomarker identification opportunity to enable select patients and speed up enrollment based on the status of immune.

Related Link: Heat Biologics Says Paid Down $1.5 Million Of Debt

The company's chief scientific officer, Taylor Schreiber, said, "The Adaptive Assay allows us to quantify the clonality of a T-cell response generated by our ImPACT platform. Future work should continue to be fruitful as we advance our understanding of the patients that benefit most from treatment."

At last check, the stock traded up by $0.06, or 5.08 percent, to $1.24 on a volume of 38,254 shares.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!